Benzinga - by Avi Kapoor, Benzinga Staff Writer.
The Dow Jones index closed higher by over 150 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
OLB Group
- The Trade: The OLB Group, Inc. (NASDAQ: OLB) Chairman and CEO Ronny Yakov acquired a total of 22,315 shares an average price of $0.75. To acquire these shares, it cost around $16,739.
- What’s Happening: On Nov. 15, the company posted a wider-than-expected quarterly loss.
- What OLB Group Does: The OLB Group Inc is a diversified fintech e-commerce merchant services provider and Bitcoin crypto mining enterprise.
- The Trade: Research Frontiers Incorporated (NASDAQ: REFR) Director Darryl Daigle acquired a total of 7,750 shares at an average price of $0.97. To acquire these shares, it cost around $7,518.
- What’s Happening: On Nov. 2, Research Frontiers posted a narrower third-quarter loss.
- What Research Frontiers Does: Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light.
Sadot Group
- The Trade: Sadot Group Inc. (NASDAQ: SDOT) Director David Errington acquired a total of 10,000 shares at an average price of $0.40. The insider spent around $3,986 to buy those shares.
- What’s Happening: On Nov. 14, Sadot Group posted upbeat quarterly sales.
- What Sadot Group Does: Sadot Group Inc operates in the food supply chain sector, connecting producers and consumers across the globe, delivering agri-commodities from producing geographies such as the Americas, Africa, and the Black Sea to consumer markets in Southeast Asia, China, and the Middle East/North Africa (MENA) region.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Forte Biosciences - The Trade: Forte Biosciences, Inc. (NASDAQ: FBRX) Director Paul A Wagner acquired a total of 29,776 shares at an average price of $0.65. The insider spent around $19,276 to buy those shares.
- What’s Happening: On Nov. 13, Forte Biosciences posted a wider third-quarter loss.
- What Forte Biosciences Does: Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease ("GvHD"), vitiligo and alopecia areata ("AA").
Don’t forget to check out our premarket coverage here
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.